Steven Kafka

Section 32 LLC (Section 32) is a venture capital firm founded in 2017 by Bill Maris. The firm is headquartered in Silicon Valley, California.

BigHat Biosciences, Inc. operates as an early-stage biotechnology company. The firm focuses on designing antibodies and other therapeutic proteins using artificial intelligence and machine learning techniques. The company was founded by Mark DePristo and Peyton Greenside in 2019 and is headquartered in San Carlos, CA.

Rome Therapeutics, Inc. develops novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome-vast stretches of uncharted genetic materials. The company was founded by Rosana Kapeller and is headquartered in Cambridge, MA.

ImmuneID, Inc. is a precision immunology company that combines next-generation sequencing with protein display technologies to develop novel therapies for immune diseases. The company's proprietary platform identifies millions of antibody-target interactions to build the map of human immunity, which helps to improve and personalize patient diagnoses for precise treatments. The company was founded in 2020 by Longwood Fund and is headquartered in Boston, MA. James S. Scibetta has been the CEO of the company since 2021.

Glympse Bio, Inc. develops modular nanoparticle sensors to create diagnostics for diseases. It uses engineered diagnostic agents that interrogate the body for certain disease states, and then carry the message to the urine for analysis. The company was founded in 2015 by Sangeeta Bhatia and Gabe A. Kwong and is headquartered in Cambridge, MA.

Sunbird Bio, Inc. is a biotech company based in Cambridge, MA. Sunbird Bio is developing protein-based diagnostic tests to empower diagnosis and treatment of Alzheimer's disease, neurological disorders, and early-stage cancer. The private company's apex technology is the first test to demonstrate the ability to detect the presence of Alzheimer's disease with a blood test. Sunbird Bio is addressing diagnostic testing to enhance patient care. The company was founded by Nicholas Ho, Carine Lim, and Huilin Shao. The CEO is John P. McDonough.

Thrive Earlier Detection Corp. operates as a healthcare company. It focuses on incorporating earlier cancer detection into routine medical care. The company was founded by Bert Vogelstein, Kenneth W. Kinzler, Isaac Kinde, Christoph S. Lengauer, and Nickolas Papadopoulos in 2019 and is headquartered in Cambridge, MA.

ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO.